China's first choice for pharmaceutical R&D outsourcing in Asia

Recently, PriceWaterhouseCoopers globally released the report “Development Trends of Pharmaceutical R&D Outsourcing in Asia”. The report pointed out that China has surpassed India to become the first choice for R&D outsourcing in Asia in terms of cost, risk and market opportunity.

According to the statistics, the average global R&D cost for a new drug is US$1.2 billion. To reduce costs, many international pharmaceutical giants have chosen to separate the non-core parts of new drug development and outsource it to developing countries. Low cost, favored by foreign companies. According to the latest report, in 2008 China's pharmaceutical R&D outsourcing market was about 260 million U.S. dollars, and it is expected to grow to 430 million U.S. dollars by 2010.

The report also pointed out that China’s low-cost labor cost advantage is gradually declining. At the same time, there are still relatively large risks, including intellectual property rights and taxation policies. In addition, as compared with Europe and the United States, Asian pharmaceutical R&D outsourcing is still ubiquitous. And other issues.